RBC Capital Maintains Outperform on Verve Therapeutics, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi maintains an Outperform rating on Verve Therapeutics (NASDAQ:VERV) but lowers the price target from $25 to $20.
August 09, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital analyst Luca Issi maintains an Outperform rating on Verve Therapeutics but lowers the price target from $25 to $20.
The Outperform rating suggests continued confidence in Verve Therapeutics' long-term prospects, but the lowered price target indicates some short-term concerns or adjustments in valuation. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100